AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03712618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - SHORT Platelet Transfusion
Description: Platelets Transfused within 60-minutes
Study NCT04429139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
Study NCT02870296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Assessment and Education
Description: Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
Study NCT00882583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
Study NCT00882583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard Radiation Therapy.
Study NCT02782052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Study NCT02782052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized combination ipratropium bromide with salbutamol
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Study NCT02782052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Placebo
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Study NCT02697227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive BATS counseling
Study NCT02697227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02697227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Receive nicotine patch
Study NCT02697227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02697227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Receive standard smoking cessation counseling
Study NCT03150966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Description: Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
Study NCT03150966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo in the form of capsules daily during 6 months study period
Study NCT05896098 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Measurement of the airway by ultrasound in obese patients.
Study NCT00907608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
Study NCT01224340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lollipop
Description: The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
Study NCT01224340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: serious games
Description: The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
Study NCT01224340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
Study NCT00002705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00185380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (BAY86-5028, G04209B)
Description: Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
Study NCT00185380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (BAY86-5028, G04209C)
Description: Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
Study NCT00185380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
Study NCT03441997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind-body exercise
Description: Exercise program.
Study NCT03441997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light mobility exercises
Description: Modified mind-body program.
Study NCT03907865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Softacort
Description: Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
Study NCT02589665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Study NCT02589665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00978380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO
Study NCT01120236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT01120236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01120236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT01120236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT01120236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01120236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03732495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Denosumab
Description: Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met
Study NCT01683292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled VR040
Study NCT01683292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VR040
Description: Placebo arm
Study NCT00922181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Liver tumors are destructed/ablated using single-probe microwave energy device
Study NCT04639492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MBS oral solution
Description: Oral BIDAC, twice a day before breakfast and dinner times
Study NCT04581369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordinator Intervention for Direct Intervention Group
Description: The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians.
Study NCT00922181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Liver tumors are destructed/ablated using radiofrequency energy device
Study NCT02612974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hirudinaria granulosa, qurse mafasil
Description: compare the efficacy of both groups
Study NCT02612974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hirudinaria granulosa, qurse mafasil
Description: compare the efficacy of both groups
Study NCT02206334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study NCT01573975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5RA-5RCM
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
Study NCT01573975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5RA-5RCT
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
Study NCT01573975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10RCA
Description: rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
Study NCT02032810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
Study NCT02032810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
Study NCT00112320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVR plus RV remodeling
Description: PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
Study NCT00112320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVR
Description: PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
Study NCT01681225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal-pressure guided mechanical ventilation
Study NCT04194944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT04194944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study NCT04194944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV
Study NCT04194944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered IV
Study NCT04194944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered IV
Study NCT04581369 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care Coordinator Intervention for Standard of Care Group
Description: For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
Study NCT03440450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
Study NCT04581369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver Intervention
Description: Caregivers of the participants will be assessed for caregiver burden at 3 time points.
Study NCT01997216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lens
Description: Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
Study NCT03156686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOME-based hospitalization
Description: patients in Home care treatment (HC) group will be treated at home
Study NCT04355442 — intervention group
Intervention type: PROCEDURE
Intervention: Facial fractures reduction or osteosynthesis
Description: Facial fractures reduction or osteosynthesis
Study NCT03130621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gene detection
Description: Next-generation sequencing
Study NCT00568373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Gastric Pacemaker
Description: Gastric Pacemaker
Study NCT02503358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02503358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02503358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02503358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT03587701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
Study NCT03587701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (Period 1)
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
Study NCT03587701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
Study NCT03587701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (Period 2)
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
Study NCT03549676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
Study NCT01519791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50.
Study NCT01681225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP mechanical ventilation
Study NCT04085809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmLactin® Rapid Relief
Description: AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
Study NCT01997216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
Study NCT02933255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/F
Description: PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
Study NCT02933255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
Study NCT02933255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
Study NCT02933255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
Study NCT02933255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Participants who experience aches or fever after vaccination may take Tylenol as directed.
Study NCT02538965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
Study NCT03361774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to.
Study NCT03361774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.